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Abstract
Background: Based on the potential of Schiff base compounds to act as sources for the development of cancer
chemotherapeutic agents, this in vivo study was performed to investigate the inhibitory properties of the synthetic Schiff
base compound Cu(BrHAP)2 on colonic aberrant crypt foci (ACF).
Methodology: This study involved five groups of male rats. The negative control group was injected with normal saline
once a week for 2 weeks and fed 10% Tween 20 for 10 weeks, the cancer control group was subcutaneously injected with
15 mg/kg azoxymethane once per week for two consecutive weeks, the positive control group was injected with 15 mg/kg
azoxymethane once per week for two consecutive weeks and 35 mg/kg 5-fluorouracil (injected intra-peritoneally) for 4
weeks, and the experimental groups were first injected with 15 mg/kg azoxymethane once per week for two consecutive
weeks and then fed 2.5 or 5 mg/kg of the Schiff base compound once a day for 10 weeks. Application of the Schiff base
compound suppressed total colonic ACF formation by up to 72% to 74% (P,0.05) when compared with the cancer control
group. Analysis of colorectal specimens revealed that treatments with the Schiff base compound decreased the mean crypt
scores in azoxymethane-treated rats. Significant elevations of superoxide dismutase, glutathione peroxidase and catalase
activities and a reduction in the level of malondialdehyde were also observed. Histologically, all treatment groups exhibited
significant decreases in dysplasia compared to the cancer control group (P,0.05). Immunohistochemical staining
demonstrated down-regulation of the PCNA protein. Comparative western blot analysis revealed that COX-2 and Bcl2 were
up-regulated and Bax was down-regulated compared with the AOM control group.
Conclusion: The current study demonstrated that the Cu(BrHAP)2 compound has promising chemoprotective activities that
are evidenced by significant decreases in the numbers of ACFs in azoxymethane-induced colon cancer.
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Introduction
Colorectal cancer, also known as large bowel cancer, can
involve aberrant growths in the appendix, colon and rectum and is
among the three most prevalent types of cancer [1]. Despite much
research and progress on the prevention and treatment of colon
cancer, significant suppression of tumors is still rarely achieved,
and treatment with known agents can lead to tumor progression in
some cases [2]. The detection and treatment of early-stage colon
cancer with proper agents plays a critical role in reducing the
number of colorectal cancer victims [3]. The azoxymethane
(AOM) model of experimental colon cancer imitates the extensive
molecular, clinical and histological features of human colon cancer
[4]. The azoxymethane (methyl-methylimino-oxidoazanium) com-
pound is an oxide of azomethane (molecular formula C2H6N2O)
and is commonly used to induce colon cancer in experimental
models [5,6].
Metal complexes have been extensively used in pharmacology
for centuries [7,8]. The development of metal-based drugs has
been promoted by significant accomplishments that have been
achieved with platinum-based antitumor agents, such as oxalipla-
tin, cisplatin and carboplatin. However treatment with platinum-
based drugs is normally associated with the evolution of drug
resistance and severe side effects during the therapy processes [9].
Copper is well known to be a vital cation for cell survival, which
plays an essential role as a cofactor of some metalloenzymes.
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Copper has been an excellent candidate for cancer treatment since
the 1960s [10]. The oxidative nature and bio-activity of copper in
humans has attracted inorganic chemists to address the pharma-
cological applications of copper (II) [11,12]. These types of metals
with the unique character of reactivation with dioxygen are used
in the body system after passing through the intestinal walls [13].
Because of their potential for DNA cleavage via oxidative or
hydrolytic mechanisms and strong interactions with DNA via
intercalation or surface associations, copper (II) complexes with
heterocyclic bases have been widely investigated [14]. Schiff bases
are a notable class of compounds with significant potential anti-
ulcer [15], antibacterial, antifungal [16,17], anti-diabetic [18],
antitumor [19–23], anti-proliferative [24,25] and anti-inflamma-
tory activities [26,27].
Schiff base-derived copper (II) complexes have strong anti-
proliferative, gastroprotective and antibacterial potential because
of the properties of their metal centers or their coordinate ligands,
which are associated with electronic and structural characteriza-
tions that are attributable to their coordination [15]. The present
study was designed to investigate the inhibitory effect of a copper
(II) complex derived from N,N’-dimethyl ethylene diamine and the
2-hydroxyacetophenone Schiff base ligand Cu(BrHAP)2 against
AOM-induced colon carcinogenesis in rats in terms of the
incidence of ACF.
Materials and Methods
Chemicals
For this experiment, the carcinogenic chemical of azoxy-
methane (AOM) was purchased from Sigma Aldrich (St. Louis,
MO, USA), and 5-fluorouracil, a colon cancer positive reference,
was purchased from Calbiochem (San Diego, CA, USA).
Synthesis of the complex
The copper complex was synthesized as previously detailed in a
published article [15]. This Cu(BrHAP)2 Schiff base compound
was attained from the Chemistry Department of the Faculty of
Science of the University of Malaya.
Ethical issues
The protocol for this study was approved by the ethics
committee for animal experimentation of the Faculty of Medicine,
University of Malaya, Malaysia (Ethic No. PM/27/07/2010/
MAA (R)). The animals were cared for according to the criteria of
the National Academy of Science’s Guide for the Care and Use of
Laboratory Animals [28,29].
Acute toxicity evaluation
To demonstrate the safety of the usage of the Cu(BrHAP)2
complex, 36 healthy female and male rats (weighed between 150–
180 g) taken from the Animal House of the Faculty of Medicine of
the University of Malaya, Kuala Lumpur, underwent acute
toxicity analysis. The rats were divided into the following three
groups: a vehicle control group, a group that received 100 mg/kg
copper (II) complex, and a group that received 2000 mg/kg
copper (II) complex [15]. After an overnight fast, the rats were fed
the copper (II) complex and were subsequently observed every two
hours over 24 hours, and any toxicity symptoms were recorded.
Mortality was recorded over the 14 days of the experiment. After
the rats were sacrificed, the blood and organs were collected for
biochemical, hematological and histological analyses.
Assessing the chemopreventive effect of copper (II)
complex
Male Sprague-Dawley rats were obtained from the Animal
House of the Faculty of Medicine, University of Malaya.
International principles and local regulations were observed
regarding the care and use of these laboratory animals. The rats
weighted approximately 180–200 grams and were received at the
approximate age of 6–8 weeks. The animals were maintained
under controlled conditions at room temperature (22–24uC) and
50–60% humidity on a 12 hr light-dark cycle with ad libitum
access to standard diet and water. The animals were acclimatized
to the standard laboratory conditions for a period of two weeks
before the initiation of any experiment.
Thirty-six adult male rats were divided randomly into the
following five groups of six rats each: a negative control group
(these rats were received subcutaneous injections of normal saline
and were orally administered 10% Tween 20 each day for 10
weeks), a cancer control group (these rats received subcutaneous
injections of 15 mg/kg AOM once per week for two consecutive
weeks. They were administered orally with 10% Tween 20 (5 mL/
kg) daily), a positive control group (these rats received subcuta-
neous injections of 15 mg/kg AOM once per week for two
consecutive weeks and followed with intra-peritoneal injections of
35 mg/kg 5-fluorouracil for 4 weeks) and two treatment groups
(these rats first received subcutaneous injections of 15 mg/kg
AOM once per week for two consecutive weeks and oral
administration of the Cu(BrHAP)2 Schiff base compound at
dosages of 2.5 mg/kg or 5 mg/kg for 10 weeks) [5]. During the
experiments, the rats were weighed and observed daily for signs of
toxicity.
Scoring of aberrant crypts
To record the incidence of ACF, the locations and numbers of
crypts were recorded 10 weeks after the last AOM injection. To do
this, the rats were killed with a high dose of xylazine and ketamine
anesthesia, and their colons were extracted and flushed with cold
phosphate-buffered saline (PBS) and then longitudinally opened
from anus to rectum. For topographic analysis, 0.2% methylene
blue was used to stain the colon, and the colon was observed
mucosal side up with a Nikon dissecting microscope. The ACF
score was calculated based on the number of aberrant crypts foci,
which are known as foci containing more than two aberrant
crypts. The number of ACF per colon and the number of aberrant
crypts in each focus were determined.
Histological classification of ACFs
Buffered formalin (10%) was used to fix the colon specimens
following processing in a paraffin tissue-processing machine (Leica,
Germany). The tissues were then embedded in paraffin blocks and
cut into 5-mm sections. The sections were stained with hematox-
ylin and eosin (H&E) and were observed with a light microscope
(Nikon, Japan).
Immunohistochemistry
After heating the tissue section slides in a hot-air oven for
25 min at 60uC, xylene and alcohol were used to de-paraffinize
and rehydrate the tissue, respectively, which was then immuno-
histochemically stained according to the manufacturer’s protocol
(Dakocytomation, USA). A peroxidase block was used to block
endogenous peroxidase (0.03% hydrogen peroxide-containing
sodium azide) and after washing with washing buffer, the slides
were incubated with diluted mouse PCNA (1:200, Cat: ab2426)
monoclonal antibody, which was provided by the Abcam
Invivo Chemopreventive Effect of Copper(II)Complex
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Company. Sufficient amounts of streptavidin–HRP were incubat-
ed with the sections for 15 min. After washing gently with washing
buffer, the sections were incubated with DAB-substrate-chroma-
gen for 5 min and then stained with hematoxylin for 5 sec. They
were then dipped in ammonia 10 times and washed with distilled
water, and the slides were mounted with a cover slip. Positive
samples displayed a brown color under a light microscope. The
PCNA labeling index (PI) was measured as the [(number of
positive cells)/(total number of epithelial cells)] X 100 for each
field. These PI values for all the different colon sections of the rats
belonging to similar groups were then averaged.
Western Blot analyses
After sacrificing the rats, the colon tissue was collected, and to
analyze protein expression through western blot analysis, proteins
were extracted using protein extraction buffer (Pierce, USA), and
the supernatant was subjected to western blot assays.
In brief, extracted proteins (30 mg) were separated on 10%
resolving polyacrylamide gels (i.e., SDS-PAGE) and electroblotted
(25 mA for 2 h). Extracted proteins were transferred to PVDF
membranes (Pierce, USA) using a Trans-Blot SD semi-dry transfer
cell (Bio-Rad, USA) at 15 V, 95 mA, for 1 h then the PVDF
membrane was blocked using Blocker Casein (Pierce, USA) for 1 h
at room temperature and washed twice using TBST. After
incubation overnight at room temperature with specific primary
antibodies (b-actin 1:10000 (Cat: ab6276), Bax 1:1000 (Cat:
ab7977), Bcl-2 1:1000 (Cat: ab183656) and COX-2 1:1000 (Cat:
ab15191), the blots were incubated for 2 h with the appropriate
peroxidase-coupled secondary antibodies, and subsequent detec-
tion was performed with XOMAT film via enhanced chemilumi-
nescence. The xerograms were digitized with an Epson scanner,
and band intensities were quantified using IP lab gel.
Antioxidant activities of colon homogenates
After washing the colon tissue samples with ice-cold saline, a
homogenate (10% w/v) was prepared in ice-cold 50 mM
phosphate buffer (pH 7.4) containing a mammalian protease
inhibitor cocktail and centrifuged at 10,0006g for 30 minutes at
4uC. Next, the supernatant was used to analyze the activities of the
catalase (CAT), glutathione peroxidase (GPX), and superoxide
dismutase (SOD) enzymes and for MDA assay. The kits were
provided by Cayman Chemical Co. (Michigan, USA).
Statistical analyses
Predictive Analysis Software (PASW) version 18 was used to
analyze the data of this study. The experimental data were
analyzed with one-way analyses of variance (ANOVAs) followed
by Tukey’s post-hoc test. The data are displayed as the means 6
the (standard error of the mean) S.E.M. The level of significance
was set at P,0.05.
Results
Acute toxicity study
As reported in our previously published article, the application
of the copper (II) Schiff base compound produced no signs of
hematology, serum biochemical abnormality, or hepatic or renal
toxicity. Thus, this complex seems to be safe for use [13].
Body weights and serum biochemistry analyses of the
chemopreventive potential of the Cu(BrHAP)2
No significant differences were observed in the rats’ body
weights across groups (Table 1). Tables 2 and 3 illustrate the serum
biochemistry analyses of the blood collected from the scarified
animals for the examination of the parameters of liver and renal
function compared to their vehicle groups.
ACF frequency
The tumor quantification analyses of the colons that were
stained with methylene blue immediately after sacrifice are
summarized in Table 4. Figure S1 displays topographic views of
the methylene blue-stained colon tissues of the different groups.
ACFs were distinguished from the surrounding normal crypts by
their increased sizes, the increased distances from the lamina to the
basal surfaces of the cells, and the easily discernible pericryptal
zones. No microscopic changes were observed in the normal
control group, and a significantly greater number of ACFs were
recorded in the cancer control group. The groups that received the
copper (II) complex exhibited significant reductions in ACF
numbers (72.2% and 74.7%; p,0.05). The distribution of ACFs in
the cancer control group was centered on the middle of the colon
in the cancer control group, and the copper (II) complex-treated
groups exhibited significantly reduced distal, middle and proximal
ACF distributions compared to the cancer control group (Table 5).
Histological evaluation
The macroscopic pathological differences in the colon tissues of
different groups indicated that the ACFs contained narrow
luminal epithelial cells and deformed goblet cells with elongated
nuclei. Losses of cell polarity and increases in mitoses were also
observed in dysplastic ACFs compared to the normal circular-
shaped cells with basally located nuclei. Histological photos of the
colon tissues from the positive control group exhibited reductions
Table 1. Effects of the copper (II) complex on body weights
in AOM-induced colon cancer.
Groups Week 1 Week 2
Negative Control group 150.263.8 355.6610.6
Cancer Control group 149.865.7 379615.8
Positive Control group 152.864.2 360.7612.3
Cu(BrHAP)2(2.5 mg/kg) 151.164.5 375.8620.3
Cu(BrHAP)2 (5 mg/kg) 153.466.3 368.469.9
The values are expressed as the mean 6 the S.E.M. There were no statistically
significant differences between the groups. P,0.05 was considered to be
significant.
doi:10.1371/journal.pone.0091246.t001
Table 2. Effects of the copper (II) complex on parameters of
renal function in AOM-induced colon cancer.
Group Urea (mmol/L) Creatinine (mmol/L)
Negative control group 5.5560.20 54.565.32
Cancer control group 5.9560.06 33.062.2
Positive control group 5.160.42 44.060.63
Cu(BrHAP)2(2.5 mg/kg) 5.560.46 33.560.57
Cu(BrHAP)2 (5 mg/kg) 5.360.82 33.960.89
The values are expressed as the mean 6 the S.E.M. There were no statistically
significant differences between the groups. P,0.05 compared to cancer control
group was considered to be significant.
doi:10.1371/journal.pone.0091246.t002
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in the numbers of cells with pathological differences, and a similar
reduction was observed in the oral copper (II) complex treatment
groups (Figure S2).
Immunohistochemistry
Immunohistochemical PCNA protein staining of the colon
sections from the azoxymethane group revealed an up-regulation
of the protein. The positive control group exhibited a lower
number of positive cells compared to the azoxymethane group,
and similar results were observed in the copper (II) complex
treated groups. The PCNA-positive cells (%) of the colon tissue in
the cancer control group were 100%, whereas PCNA-positive cells
(%) from the treated group were 47.4% and 35.4%, respectively
(p,0.05) (Figure 1).
Western blot analyses
Western blot analyses revealed that the Bax (23 kDa) protein
was down-regulated in the cancer control group and that the
Cu(BrHAP)2 complex increased the expression of this protein. The
Cu(BrHAP)2 complex and 5-fluorouracil caused down-regulations
of COX-2 (69 kDa) and Bcl2 (26 kDa) proteins in the treated rats
compared to the cancer control group. Protein expressions from
western blots were quantitated using the Image J software
program. The densities for the cancer group (A) were set to 1
and the relative densities for the positive and treated groups were
plotted. The data are the mean 6 SEM. Statistical significance
was expressed as p,0.05 (Figure 2).
Antioxidant enzyme activities
The Cu(BrHAP)2 complex significantly increased the levels of
SOD, CAT and GPX in homogenized colon samples compared to
those of the cancer control group (p,0.05). The level of MDA was
significantly decreased in the Schiff base complex-treated groups,
and the cancer control group exhibited an up-regulation of the
expression level of MDA (p,0.05) (Figure 3).
Discussion
Anticancer drug discovery based on biological strategies of using
transitional metal chemistry to target cancer growth pathways and
activate cancer cell apoptosis have been developed to decrease the
severity of cancer in patients [30,31].
According to recent research that suggests that to control cancer
growth, it is not enough to rely on a single cellular or physiological
event, looking for the agents with a controlling role in multiple
tumorigenic events and associated mechanisms is extremely
important [32,33]. Schiff base groups of compounds have been
extensively studied for their chemoprotective effects. The copper
complex has the ability to inhibit cells’ activities relevant to cell
proliferation, and thus deduce the proliferation markers and the
elevation of apoptosis pathways [10,15]. The previous studies
reported that proteasome inhibitors induce apoptosis and have
potential anticarcinogenic roles [34,35]. A study by Xiao et al. [36]
revealed the inhibitory role of Schiff base copper against
proteosome activity, allowing the induction of apoptosis to
increase.
In the present study, we demonstrated that Cu(BrHAP)2 can
reduce ACF formation and therefore colon tumor incidence in
rats. Mechanistically, the compound showed promising chemo-
preventive effects against ACF formation by inhibiting tumor cell
proliferation and controlled the expression of specific key proteins
and mitochondrial apoptosis induction. It appears that controlling
the antioxidant enzymes’ expression levels with the compound
plays an important role in inhibiting ACF formation (Figures 1, 2,
3).
When animal models are used in the study, clinical and
toxicological investigations of new synthetic compounds are crucial
Table 3. Effects of the copper (II) complex on liver function in AOM-induced colon cancer.
Groups Total protein (g/L) Albumin (g/L) AST (IU/L) ALT (IU/L) GGT(IU/L)
Negative control group 67.3260.34 12.2760.54 207.262.53 6362.38 5.560.3
Cancer control group 69.560.39 9.060.31 229.667.2 69.560.68 3.760.6
Positive control group 73.662.1 11.360.89 182.064.5 50.060.92 6.160.48
Cu(BrHAP)2 (2.5 mg/kg) 68.560.67 10.560.4 209.566.1 64.260.63 4.160.1
Cu(BrHAP)2 (5 mg/kg) 70.961.1 11.360.42 212.0610.6 62.063.4 4.360.32
The values are expressed as the mean 6 the SEM There were no significant differences between groups. The significance value was set at P , 0.05 compared to the
cancer control group. TB: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: g-glutamyl transferase.
doi:10.1371/journal.pone.0091246.t003
Table 4. Effects of the copper (II) complex on AOM-induced colonic ACFs containing four or more aberrant crypts.
Treatment group No. of crypts per ACF Total ACF Inhibition %
1 crypt 2 crypt 3 crypt 4 crypt and more
Negative control group 0.0 0.0 0.0 0.0 0.0 0.0
Cancer control group 560.43 2663.27 1963.27 2961.27 7966.7 0
Positive control group 160.03* 560.69* 460.64* 860.26* 1862.81* 77.2*
Cu(BrHAP)2 (2.5 mg/kg) 660.71* 560.14* 260.19* 1061.04* 2262.70* 72.2*
Cu(BrHAP)2 (5 mg/kg) 260.41* 460.52* 360.27* 1161.13* 2061.53* 74.7*
The values are expressed as the mean 6 the S.E.M. The significance value was set at P, 0.05 compared to the cancer control group.
doi:10.1371/journal.pone.0091246.t004
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for ensuring the safety and efficacy of these compounds. As
reported in our previously published article, the LD50 of
Cu(BrHAP)2 observed in this study can be considered to be safe
based on the global harmonized system of the classification and
labeling of chemicals [15,28]. Thus, our results demonstrated the
toxicological safety of the oral administration of this compound
because there were no signs of behavioral abnormalities or weight
loss. No significant differences were found in the treated groups
compared to the control group in terms of liver and renal function.
Thus, our findings support the logical use of this new synthetic
Schiff base compound.
The carcinogenic compound dimethyl diazene-1-oxide (azox-
ymethane) has been proven to be capable of producing colon
tumors after administration to male rats for a specified period of
time [37]. The sizes and numbers of aberrant crypt foci are used as
intermediate biomarkers and correlate with the risk of developing
colon cancer. Thus, sizes and numbers of aberrant crypt foci
provide a quick measure for screening compounds that might be
Table 5. Effects of the copper (II) complex on the regional
distribution of colonic ACF in AOM-induced colonic cancer.
Groups
ACF
Counting Total
Proximal Middle Distal
Negative control group 0.0 0.0 0.0 0.0
Cancer control group 2563.66 4365.77 1163.79 7966.7
Positive control group 0 0060.0* 1862.37* 0 0060.0* 1862.81*
Cu(BrHAP)2 (2.5 mg/kg) 761.04* 1367.89* 260.5* 2262.70*
Cu(BrHAP)2 (5 mg/kg) 0 0060.0* 2064.84* 060.0* 2061.53*
The values are expressed as the mean 6 the S.E.M. The significance value was
set at P, 0.05 compared to the cancer control group.
doi:10.1371/journal.pone.0091246.t005
Figure 1. Immunohistochemical analyses of the expression of PCNA in the colon tissues. A) Normal colon mucosa. B) Colon mucosa of the
group exposed to AOM. C) Colon mucosa of the group treated with 5-fluorouracil. D) Colon mucosa of the group treated with 2.5 mg/kg copper (II)
complex. E) Colon mucosa of the group treated with 5 mg/kg copper (II) complex. Immunohistochemical staining for PCNA protein revealed a down-
regulation of PCNA protein in the rats treated with the Cu(BrHAP)2 complex. Magnification: 100x. All values are expressed as the means 6 the
standard error of mean. The mean difference was significant at the p,0.05 level compared to the cancer control group.
doi:10.1371/journal.pone.0091246.g001
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effective in suppressing the development of colon cancer [38–40].
As explained previously, through the induction of apoptosis
activation via the mitochondrial pathway, the copper complex has
the ability to prevent cancers [10]. The present study revealed that
the administration of Cu(BrHAP)2 at doses of 2.5 mg/kg and
5 mg/kg significantly reduced total AOM-induced colonic ACF
formation and multicrypt aberrant crypt growth by 72% and 74%
(p,0.05), respectively.
The presence of PCNA was used as a marker of cell
proliferation (which plays an important role in cancer progression)
in the colon tissues because PCNA indicates a cell’s extra division
capability [41–43]. Studies in animal models showed that
abnormal epithelial cell proliferation is one of the earliest
indications of pre-neoplasia [44–45]. Based on a study by
Deschner EE et al. [46], animals treated with any chemical colon
carcinogen revealed a larger proliferation zone and a higher
labeling index compared with the vehicle-treated group. Accord-
ing to the immunohistochemical results of this investigation,
Cu(BrHAP)2 induced colon tissue protection by down-regulating
PCNA. Therefore, the groups treated with the compound had a
smaller proliferation zone and a lower labeling index, so the cells
were no longer in the growth cycle (p,0.05). A similar reduction in
proliferating cell nuclear antigen was reported previously in a
study that demonstrated successful chemoprevention against
AOM-induced colon cancer in an animal model [47]. Thus, the
compound used in this experiment may inhibit ACF formation by
modifying cell proliferation. Multiple factors in the immune
apoptosis pathway play critical roles in the survival or death of
cells, and these factors interact to affect the final outcomes [47].
The induction of colon cancer with AOM causes oxidative injuries
following lipid peroxidation production in colon cells and
erythrocytes, which cause increased secretion of total protein
and albumin via the kidney, which, in turn, results in the elevation
of urea concentrations in the blood. This process may play a role
in the etiology of colon cancer in rats [48–49] The balance
between the ROS levels in the body is essential for cellular
function and the apoptotic pathway in precancerous cells [50]. If
there is no effective regulation, the excess ROS would damage
proteins, lipids or DNA and in turn inhibit the normal function
and modulation of gene expression, cell cycle, cell metabolism, cell
adhesion and cell death [51]. The Schiff based compound used in
this study is presumed to have the ability to counterbalance these
ROSs. The mechanism of action of this compound might be
through free radical scavenging and quenching of the formation of
singlet oxygen, which protects the colon against oxidative stress
and stimulated colon repair mechanisms. There is a possibility that
the compound possesses protective effects against ACF formation
and colon injury through the endogenous oxidative enzyme
systems involved in the colon defense system, such as (CAT),
(SOD) and (GPX), which counterbalance the oxidative stress
induced by AOM. In this study, it was demonstrated that AOM
administration caused severe damage to the rat’s endogenous
antioxidant system, represented by the disturbance of oxidative
stress enzymes (CAT, SOD and GPX) activities which led to a
decrease in their levels, alongside lipid peroxidation that was
characterized by up-regulation in MDA levels.
Previous studies have proven the role of the increased activities
of antioxidant enzymes (SOD, CAT and GPX), which are induced
by antitumor agents, in the mechanism of chemopreventive
therapy [52]. The in vivo evaluation of antioxidants performed in
Figure 2. Western blot analyses of Bax, Bcl-2 and COX-2. A) Colon mucosa of the group exposed to AOM. B) Colon mucosa of the group
treated with 5-fluorouracil. C) Colon mucosa of the group treated with 2.5 mg/kg copper (II) complex. D) Colon mucosa of the group treated with
5 mg/kg copper (II) complex. COX-2 and Bcl2 expression was increased and Bax expression was decreased in the treatment group compared to the
AOM control group. b-actin was used as an internal control to confirm equal sample loading. The Image J program was used to evaluate protein
expression. All values are expressed as the means6 the standard error of mean. The mean difference was significant at the p,0.05 level compared to
the cancer control group.
doi:10.1371/journal.pone.0091246.g002
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this study demonstrated significant elevations in the SOD, CAT
and GPX activities in the groups treated with Cu(BrHAP)2.
However, reduced lipid peroxidation suggested a significant
decrease in MDA levels. Although this result was not significant
due to the effect of Cu(BrHAP)2 on the neutralization of the toxic
compounds that are produced by converting AOM to a highly
toxic metabolite, the levels of total protein, albumin and urea were
restored to normal values [53]. To further investigate the
chemopreventive activity of this compound in colon cancer and
the mechanism underlying this effect, the expressions of Bax,
proapoptotic proteins, B-cell lymphoma 2 (Bcl-2) (which has
antiapoptotic effects) and cyclooxygenase 2 (COX-2) in the
different groups were analyzed. Western blot assay was used in
this study to detect specific proteins in the homogenized extracted
colon. These proteins play essential roles in the development of
new cancer drugs [54]. Bcl-2 plays a vital role in controlling the
process of cell death by blocking various apoptosis signals. In
contrast, the Bax protein has a role in the release of a factor that
promotes apoptosis into the cytoplasm. Thus, the balance of the
expressions of Bcl-2 and Bax is important in the process of cell
death [52–55]. COX-2 has been reported to be overexpressed in
the early stage, and COX-2 levels have been reported to increase
with the progression of cancer. COX-2 is the rate-limiting enzyme
in the biosynthesis of prostanoids, which increase proliferation,
apoptotic resistance and angiogenesis during colonic carcinogen-
esis. The expression of COX-2 was upregulated in the AOM-
induced colonic tumors. Down-regulation of COX-2 has been
demonstrated to have a crucial role in the anticancer agent-
induced suppression of AOM-induced tumorigenesis in an animal
model [53]. Our results revealed that Cu(BrHAP)2 increased the
expression of the BAX protein, which is inconsistent with a
previous study by Zhang et al. [56] who reported that the induction
of BAX protein expression led to cell apoptosis using Schiff base
copper compound, and down-regulated the expression of COX-2
and Bcl-2 proteins, and this pattern of expression changes strongly
suggests that apoptosis will be induced via the mitochondrial
pathway. Ma et al. [10] also demonstrated the anti-cancer effect of
a novel Schiff base copper (II) complex through the activation of
the mitochondrial pathway. The result of this study was similar
with our previous published research on the same compound,
which revealed its effective role on gastro-prevention. The result
demonstrated that the complex was able to significantly reduce the
Bax protein expression [15]. Previous evaluations of effective
chemopreventive agents have also revealed the same pattern of
Bax, Bcl-2, and COX-2 protein expression [52,53].
Figure 3. Effects of the copper (II) complex on antioxidant enzyme activities. A) Negative colon group, B) group exposed to AOM, C) group
treated with 5-fluorouracil, D) group treated with 2.5 mg/kg copper (II) complex, E) group treated with 5 mg/kg copper (II) complex. All values are
expressed as the means 6 the standard error of mean. The mean difference was significant at p,0.05 compared to the cancer control group.
doi:10.1371/journal.pone.0091246.g003
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Conclusions
Based on the result of this study, the chemopreventive potential
of Cu(BrHAP)2 was demonstrated by reductions in the numbers of
ACFs which could be attributed to the down-regulation of cell
proliferation-promoting proteins in cancer cells and the elevation
of the levels of antioxidant enzymes. Western blot analyses
revealed that the copper (II) complex activated apoptosis via the
mitochondrial pathway by down-regulating COX-2 and Bcl-2 and
up-regulating Bax.
Supporting Information
Figure S1 Topographical views of colon mucosa. A)
Normal colon mucosa. B) Colon mucosa of the group exposed to
AOM. C) Colon mucosa of the group treated with 5-fluorouracil.
D) Colon mucosa of the group treated with 2.5 mg/kg copper (II)
complex. E) Colon mucosa of the group treated with 5 mg/kg
copper (II) complex. Rat colonic tissue was stained with methylene
blue. Magnification: 20x.
(TIF)
Figure S2 Histological study of colon cancer in rats. A)
Normal colon mucosa. B) Colon mucosa of the group exposed to
AOM.C) Colon mucosa of the group treated with 5-fluorouracil.
D) Colon mucosa of the group treated with 2.5 mg/kg copper (II)
complex. E) Colon mucosa of the group treated with 5 mg/kg
copper (II) complex. The sections were cut parallel to the muscle
layer. H & E staining, 1006magnification.
(TIF)
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